Hans J. Hammers
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 86
- Pancreatic and Hepatic Oncology Research 28
- CAR-T cell therapy research 13
- Pulmonary and Respiratory Medicine top 0.2%
- Renal cell carcinoma treatment 157
- Prostate Cancer Treatment and Research 14
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 57
- Immunology top 2%
- Molecular Biology top 2%
- Renal and related cancers 37
-
- Economic and Financial Impacts of Cancer 21
Hans J. Hammers
201 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 4.4k
- Pulmonary and Respiratory Medicine 4.1k
- Cancer Research 1.9k
- Immunology 1.2k
- Molecular Biology 3.0k
Countries citing papers authored by Hans J. Hammers
This map shows the geographic impact of Hans J. Hammers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Hammers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Hammers more than expected).
Fields of papers citing papers by Hans J. Hammers
This network shows the impact of papers produced by Hans J. Hammers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Hammers. The network helps show where Hans J. Hammers may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hans J. Hammers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2025 | 2 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 6 | |
| 6 | 2024 | 2 | |
| 7 | 2023 | 19 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 0 | |
| 10 | 2022 | 16 | |
| 11 | 2022 | 18 | |
| 12 | 2021 | 25 | |
| 13 | 2020 | 24 | |
| 14 | 2020 | 3 | |
| 15 | 2020 | 15 | |
| 16 | Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Studybreakdown → | 2017 | 348 |
| 17 | 2017 | 76 | |
| 18 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trialbreakdown → | 2014 | 865 |
| 19 | 2012 | 89 | |
| 20 | Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model | 2008 | 1 |
About Hans J. Hammers
Hans J. Hammers is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 216 papers that have together received 8.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (157 papers), Cancer Immunotherapy and Biomarkers (86 papers), Cancer Genomics and Diagnostics (57 papers), Renal and related cancers (37 papers), Pancreatic and Hepatic Oncology Research (28 papers), Economic and Financial Impacts of Cancer (21 papers), Prostate Cancer Treatment and Research (14 papers) and CAR-T cell therapy research (13 papers). The work is most often cited by research in Oncology (4.4k citations), Pulmonary and Respiratory Medicine (4.1k citations) and Cancer Research (1.9k citations). Hans J. Hammers has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Brian I. Rini, Роберто Пили, David F. McDermott, Elizabeth R. Plimack, Saby George, Robert J. Motzer, Michael A. Carducci, Ian M. Waxman, Martin H. Voss and Asim Amin. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Genitourinary Cancer and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.